StreetAlpha.app
Home › Stocks › OCS

Oculis Holding AG (OCS)

Healthcare
$7.51
▼ −1.57%
LAST CLOSE · NOV 17

Oculis develops late stage drug candidates for eye and optic nerve diseases, based in Zug, Switzerland. It last closed at $7.51 on Nov 17, down 1.57% on the day. The average 12-month price target from 2 analysts is $39.50 (+426.0% from the last close), with a high of $40.00 and a low of $39.00.

AI Auto Pilots
Is OCS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−CHF 99.0M
Free cash flow
−CHF 66.6M
Balance sheet
Cash & equivalents
CHF 81.3M
At Dec 31
Shareholder equity
CHF 196.1M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −CHF 18.6M−CHF 18.6MFY2021FY2022: −CHF 38.7M−CHF 38.7MFY2022FY2023: −CHF 88.8M−CHF 88.8MFY2023FY2024: −CHF 85.8M−CHF 85.8MFY2024FY2025: −CHF 99.0M−CHF 99.0MFY2025

From OCS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 4). Last 12 months adds up the four latest quarters. Figures are in CHF. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated OCS in the past 90 days, not enough for a consensus
Average 12-month target
$39.50
▲ 426.0% upside

Based on 2 analysts who set a price target on OCS in the past 90 days. The average target is $39.50, with a high of $40.00 and a low of $39.00, compared with the last close of $7.51.

Low $39.00Avg $39.50High $40.00
Blue marker: last close $7.51
Highest target$40.00
Average target$39.50
Lowest target$39.00
Latest rating changes
HC Wainwright & Co.Reiterated
Nov 17Buy$39
GuggenheimTarget lowered
Nov 4Buy$45 → $40
HC Wainwright & Co.Target raised
Sep 18Buy$26 → $39
JP MorganTarget lowered
Aug 14Buy$23 → $20
HC Wainwright & Co.Maintained
Aug 5Buy$26
DateFirmActionRatingPrice target
Nov 17HC Wainwright & Co.ReiteratedBuy$39
Nov 4GuggenheimTarget loweredBuy$45 → $40
Sep 18HC Wainwright & Co.Target raisedBuy$26 → $39
Aug 14JP MorganTarget loweredBuy$23 → $20
Aug 5HC Wainwright & Co.MaintainedBuy$26
Loading…

Technical Analysis

OCS · as of the Nov 17 close · updated after every close
Downtrend

The stock is 3% below its 20 day and 14% below its 50 day average. It is 135% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot at $7.47, and the nearest resistance the 20 day average at $7.72.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.6%/day
Key levels
$34.4852 week high+359.1%
$17.65200 day average+135.0%
$10.56100 day average+40.6%
$8.5650 day average+14.0%
$8.04Swing high (Nov 9)+7.1%
$7.85Pivot R1+4.5%
$7.7220 day average+2.8%
$7.51Last close
$7.47Pivot−0.5%
$7.13Pivot S1−5.1%
$7.11Swing low (Oct 14)−5.3%
$6.7852 week low−9.7%
Indicators
RSI (14)42.38Middle of its rangeNeutral
MACD-0.29Above its signal lineBullish
Stochastic39.5Middle of its rangeNeutral
ADX (14)22.5Weak trend
Williams %R-64.6Oversold below −80, overbought above −20Neutral
CCI (20)-76.3Oversold below −100, overbought above 100Neutral
Rate of change−1.6%Change over 10 sessionsBearish
ATR (14)$0.57Typical daily range, 7.6% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCS

What happened before

See how OCS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OCS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OCS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OCS in the last 90 days.

Loading…

See today’s whale options flow across the market →

OCS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲41 buying vs 27 selling
  • ▲Shares held by funds +7.9%
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding6860+13.3%
In funds' top 1034−25.0%
Held by funds–––
New / increased19 / 2222 / 23−8.9%
Reduced / sold out17 / 109 / 180.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OCS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCS is in one of them and how their past OCS trades turned out.

OCS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OCS in an article yet. Here's the latest on the wider market.

About Oculis Holding AG

Oculis is a biopharmaceutical company based in Zug, Switzerland, with operations in the U.S. and Iceland. It develops drug candidates for diseases of the eye and optic nerve. Its pipeline includes OCS-01, an eye drop being studied for diabetic macular edema, Licaminlimab, a topical treatment for dry eye disease, and Privosegtor, a neuroprotective candidate for optic neuritis and a related nerve condition. Its intended customers are patients and eye care doctors.

Headquarters
Zug, Switzerland